Generic Entereg Availability

Entereg is a brand name of alvimopan, approved by the FDA in the following formulation(s):

ENTEREG (alvimopan - capsule;oral)

  • Manufacturer: CUBIST PHARMS
    Approval date: May 20, 2008
    Strength(s): 12MG [RLD]

Has a generic version of Entereg been approved?

No. There is currently no therapeutically equivalent version of Entereg available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Entereg. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Peripherally selective piperidine carboxylate opioid antagonists
    Patent 5,250,542
    Issued: October 5, 1993
    Inventor(s): Cantrell; Buddy E. & Zimmerman; Dennis M.
    Assignee(s): Eli Lilly and Company
    3,4,4-trisubstitutedpiperidinyl-N-alkylcarboxylates and intermediates for their preparation are provided. These piperidine-N-alkylcarboxylates are useful as peripheral opioid antagonists.
    Patent expiration dates:
    • March 29, 2016
      ✓ 
      Patent use: A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
    Patent 5,434,171
    Issued: July 18, 1995
    Inventor(s): Frank; Scott A. & Prather; Douglas E. & Ward; Jeffrey A. & Werner; John A.
    Assignee(s): Eli Lilly and Company
    This invention relates to a process for preparing certain 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates, intermediates, and congeners. Finally, the invention provides new 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates with formulations and methods for using the compounds.
    Patent expiration dates:
    • December 8, 2013
      ✓ 
      Patent use: A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Methods for the treatment and prevention of ileus
    Patent 6,469,030
    Issued: October 22, 2002
    Inventor(s): John J.; Farrar & Peter J.; Schied & William K.; Schmidt & Randall L.; Carpenter
    Assignee(s): Adolor Corporation
    Methods for the treatment and/or prevention of ileus are disclosed. The methods comprise administering to a patient an effective amount of a peripheral mu opioid antagonist compound. Preferred compounds for use in the methods include piperidine-N-alkylcarboxylates.
    Patent expiration dates:
    • November 29, 2020
      ✓ 
      Patent use: A METHOD OF TREATING OR PREVENTING ILEUS
  • Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug
    Patent 8,112,290
    Issued: February 7, 2012
    Inventor(s): Maurer; George Raymond & Jones; Robert Barnett
    Assignee(s): Adolor Corporation
    Novel methods for delivering a drug to hospital patients for short-term in-hospital use while minimizing long-term use of the drug. Embodiments are provided in which hospitals are identified which may be eligible to treat patients, for example, perform certain types of surgery, and which have measures in place to limit use of the drug to short-term use. The identified hospitals are preferably registered in a storage medium, including computer readable storage media, and may be authorized to receive the shipments of the drug. The received drug may then be dispensed to the patient.
    Patent expiration dates:
    • July 31, 2030
      ✓ 
      Patent use: ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
  • Methods for delivering a drug to a hospital patient for short-term use while minimizing long-term use of the drug
    Patent 8,645,160
    Issued: February 4, 2014
    Assignee(s): Adolor Corporation
    Novel methods for delivering a drug to hospital patients for short-term in-hospital use while minimizing long-term use of the drug. Embodiments are provided in which hospitals are identified which may be eligible to treat patients, for example, perform certain types of surgery, and which have measures in place to limit use of the drug to short-term use. The identified hospitals are preferably registered in a storage medium, including computer readable storage media, and may be authorized to receive the shipments of the drug. The received drug may then be dispensed to the patient.
    Patent expiration dates:
    • June 18, 2029
      ✓ 
      Patent use: TREATING A SUBJECT UNDERGOING ABDOMINAL SURGERY BY ADMINISTERING ALVIMOPAN TO ACCELERATE THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • October 18, 2016 - CLINICAL TRIAL STUDY RESULTS

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web4)